Telavancin.

Drugs
Katherine A Lyseng-Williamson, Stephanie K A Blick

Abstract

Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous telavancin 10 mg/kg once daily (administered as a 1-hour infusion) was effective in the treatment of adult patients with cSSSIs, including those with infections caused by MRSA, as shown by clinical cure rates in clinically evaluable, all-treated and microbiologically evaluable populations at the test-of-cure (TOC) visit. Telavancin 10 mg/kg once daily was noninferior to intravenous vancomycin 1 g every 12 hours, with clinical cure rates of 88% versus 87% at the TOC visit in pooled data from the clinically evaluable population (n = 1489) of two phase III trials. Pooled clinical cure rates in telavancin recipients at the TOC visit were also not significantly different from those in vancomycin recipients in the all-treated or microbiologically evaluable populations, including microbiologically evaluable subgroups with baseline infections caused by MRSA, meticillin-susceptible S. aureus or other Gram-positive pathogens. T...Continue Reading

References

Oct 25, 2003·Antimicrobial Agents and Chemotherapy·John L PaceKoné Kaniga
Jun 17, 2004·Journal of Clinical Pharmacology·Steven BarriereJoel Morganroth
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Sharath S HegdeJ Kevin Judice
Aug 12, 2004·The Journal of Antibiotics·Michael R LeadbetterJ Kevin Judice
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·J P ShawS Barriere
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN FAST Investigator Group
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L StevensUNKNOWN Infectious Diseases Society of America
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·Heather K SunDavid P Nicolau
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Martin E StryjewskiUNKNOWN FAST 2 Investigator Group
Jun 26, 2007·The Journal of Antimicrobial Chemotherapy·Louis D SaravolatzLeonard B Johnson
Nov 9, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ryan J Attwood, Kerry L LaPlante
Feb 6, 2008·Diagnostic Microbiology and Infectious Disease·Brian T TsujiMichael J Rybak
Apr 30, 2008·Antimicrobial Agents and Chemotherapy·Kevin M KrauseBret M Benton
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study
May 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E Stryjewski, Henry F Chambers
Jul 19, 2008·The Journal of Antimicrobial Chemotherapy·Irene Yu LubenkoAlexander A Firsov
Jan 7, 2009·Antimicrobial Agents and Chemotherapy·G A Pankuch, P C Appelbaum
Jul 8, 2009·Antimicrobial Agents and Chemotherapy·Sydney M FinegoldDenise R Molitoris
Jul 22, 2009·Antimicrobial Agents and Chemotherapy·Klaudia Kosowska-ShickPeter C Appelbaum

❮ Previous
Next ❯

Citations

Aug 15, 2014·The Journal of Antibiotics·Mark S ButlerMatthew A Cooper
Oct 22, 2013·Natural Product Reports·Armin Bauer, Mark Brönstrup
Jul 4, 2013·Chemical Biology & Drug Design·Sandeep LohanGopal S Bisht
Sep 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Federico Pea
Sep 28, 2017·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David E NixBrian L Erstad
Jan 25, 2018·ACS Infectious Diseases·Mark A T BlaskovichMatthew A Cooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Expert Opinion on Pharmacotherapy
Esteban C Nannini, Martin E Stryjewski
Expert Opinion on Investigational Drugs
Matteo BassettiClaudio Viscoli
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Louis D SaravolatzLeonard B Johnson
© 2022 Meta ULC. All rights reserved